Sue Bell was one of the first patients to receive the Alzheimer's drug lecanemab in 2020 as part of the clinical trial. It didn't stop the disease.
Copyright 2025 NPR
Jon Hamilton is a correspondent for NPR's Science Desk. Currently he focuses on neuroscience and health risks.
